--194. A formulation according to Claim 101 wherein said lipid vesicles comprise a phospholipid.

195. A formulation according to Claim 194 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.

196. A formulation according to Claim 195 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

197. A formulation according to Claim 196 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.

198. A formulation according to Claim 195 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoyl-phosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.

199. A formulation according to Claim 198 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.

200. A formulation according to Claim 195 wherein said phosphatidic acid comprises dipalmitoylphosphatidic acid.

201. A formulation according to Claim 194 wherein said lipid vesicles further comprise a polymer.

202. A formulation according to Claim 201 wherein said polymer comprises a hydrophilic polymer.

203. A formulation according to Claim 202 wherein said polymer comprises polyethylene glycol.

204. A formulation according to Claim 100 wherein said vesicles comprise protein vesicles.

205. A formulation according to Claim 204 wherein said protein comprises albumin.

206. A formulation according to Claim 100 wherein said vesicles comprise polymer vesicles.

207. A formulation according to Claim 206 wherein said polymer comprises synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, ε-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, propylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.

208. A formulation according to Claim 206 wherein said polymer comprises synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(ε-caprolactone), epoxy resin, poly(ethylene oxide), poly(propylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethyl-methacrylate and polystyrene-polyacrylonitrile.

209. A formulation according to Claim 208 wherein said polymer comprises polyvinylidene-polyacrylonitrile copolymer.

210. A formulation according to Claim 100 wherein said fluorinated gas comprises a perfluorocarbon.

211. A formulation according to Claim 210 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

212. A formulation according to Claim 211 wherein said perfluorocarbon gas is selected from the group consisting of perfluoropropane and perfluorobutane.

213. A formulation according to Claim 212 wherein said perfluorocarbon gas comprises perfluorobutane.

214. A formulation according to Claim 103 wherein said gaseous precursor has a boiling point of greater than about 37°C.

215. A formulation according to Claim 214 wherein said gaseous precursor comprises a perfluorocarbon.

216. A formulation according to Claim 215 wherein said perfluorocarbon is selected from the group consisting of perfluoropentane and perfluorohexane.

217. A formulation according to Claim 100 wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material.

218. A formulation according to Claim 217 wherein said targeting ligand is selected from the group consisting of proteins, peptides and saccharides.

219. A formulation according to Claim 218 wherein said targeting ligand is selected from the group consisting of proteins and peptides.

220. A formulation according to Claim 219 wherein said targeting ligand comprises a peptide.

221. A formulation according to Claim 220 wherein said peptide comprises a sequence selected from the group consisting of Arg-Gly-Asp and Lys-Gln-Ala-Gly-Asp-Val. SEQ ID NO1

222. A formulation according to Claim 219 wherein said targeting ligand comprises the sequence Arg-Gly-Asp.

223. A formulation according to Claim 100 wherein said receptors comprise the glycoprotein GPIIbIIIa receptor.

224. A formulation according to Claim 223 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of no greater than about 10^{-3} molar.

225. A formulation according to Claim 224 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of less than about 10^{-3} molar.

226. A formulation according to Claim 225 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-9} molar to less than about 10^{-3} molar.

227. A formulation according to Claim 226 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-7} molar to about 10^{-5} molar.

228. A formulation according to Claim 227 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of about 10^{-6} molar.

229. A process according to Claim 114 wherein said lipid vesicles comprise a phospholipid.

230. A process according to Claim 229 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidyl-ethanolamine and phosphatidic acid.

231. A process according to Claim 230 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

232. A process according to Claim 231 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.

233. A process according to Claim 230 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidyl-ethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoyl-phosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophospho-ethanolamine.

234. A process according to Claim 233 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.

235. A process according to Claim 230 wherein said phosphatidic acid comprises dipalmitoylphosphatidic acid.

236. A process according to Claim 114 wherein said lipid vesicles further comprise a polymer.

237. A process according to Claim 236 wherein said polymer comprises a hydrophilic polymer.

238. A process according to Claim 237 wherein said polymer comprises polyethylene glycol.

239. A process according to Claim 113 wherein said vesicles comprise protein vesicles.

240. A process according to Claim 239 wherein said protein comprises albumin.

241. A process according to Claim 113 wherein said vesicles comprise polymer vesicles.

242. A process according to Claim 241 wherein said polymer comprises synthetic polymers or copolymers which are prepared from monomers

selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, ε-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, propylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.

A1 cont.

243. A process according to Claim 241 wherein said polymer comprises synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(ε-caprolactone), epoxy resin, poly(ethylene oxide), poly(propylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethyl-methacrylate and polystyrene-polyacrylonitrile.

244. A process according to Claim 243 wherein said polymer comprises polyvinylidene-polyacrylonitrile copolymer.

245. A process according to Claim 113 wherein said fluorinated gas comprises a perfluorocarbon.

246. A process according to Claim 245 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

247. A process according to Claim 246 wherein said perfluorocarbon gas is selected from the group consisting of perfluoropropane and perfluorobutane.

248. A process according to Claim 247 wherein said perfluorocarbon gas comprises perfluorobutane.

249. A process according to Claim 113 wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material.

250. A process according to Claim 249 wherein said targeting ligand is selected from the group consisting of proteins, peptides and saccharides.

251. A process according to Claim 250 wherein said targeting ligand is selected from the group consisting of proteins and peptides.

252. A process according to Claim 251 wherein said targeting ligand comprises a peptide.

253. A process according to Claim 252 wherein said peptide comprises a sequence selected from the group consisting of Arg-Gly-Asp and Lys-Gln-Ala-Gly-Asp-Val. SEQ ID NO 1

254. A process according to Claim 253 wherein said targeting ligand comprises the sequence Arg-Gly-Asp.

255. A process according to Claim 113 wherein said receptors comprise the glycoprotein GPIIbIIIa receptor.

256. A process according to Claim 255 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of no greater than about 10^{-3} molar.

257. A process according to Claim 256 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of less than about 10^{-3} molar.

258. A process according to Claim 257 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-9} molar to less than about 10^{-3} molar.

259. A process according to Claim 258 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-7} molar to about 10^{-5} molar.

260. A process according to Claim 259 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of about 10^{-6} molar.

261. A targeted formulation according to Claim 123 wherein said lipid vesicles comprise a phospholipid.

262. A targeted formulation according to Claim 261 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.

263. A targeted formulation according to Claim 262 wherein said phosphatidylcholine is selected from the group consisting of

dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

264. A targeted formulation according to Claim 263 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.

265. A targeted formulation according to Claim 262 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoyl-phosphatidylethanolamine, dioleoylphosphatidyl-ethanolamine, N-succinyldioleoyl-phosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.

266. A targeted formulation according to Claim 264 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanol-amine.

267. A targeted formulation according to Claim 262 wherein said phosphatidic acid comprises dipalmitoylphosphatidic acid.

268. A targeted formulation according to Claim 123 wherein said lipid vesicles further comprise a polymer.

269. A targeted formulation according to Claim 268 wherein said polymer comprises a hydrophilic polymer.

270. A targeted formulation according to Claim 269 wherein said polymer comprises polyethylene glycol.

271. A targeted formulation according to Claim 122 wherein said vesicles comprise protein vesicles.

272. A targeted formulation according to Claim 271 wherein said protein comprises albumin.

273. A targeted formulation according to Claim 122 wherein said vesicles comprise polymer vesicles.

274. A targeted formulation according to Claim 273 wherein said polymer comprises synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, ε-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, propylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.

275. A targeted formulation according to Claim 274 wherein said polymer comprises synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(ε-caprolactone), epoxy resin, poly(ethylene oxide), poly(propylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethyl-methacrylate and polystyrene-polyacrylonitrile.

276. A targeted formulation according to Claim 275 wherein said polymer comprises polyvinylidene-polyacrylonitrile copolymer.

277. A targeted formulation according to Claim 122 wherein said fluorinated gas comprises a perfluorocarbon.

278. A targeted formulation according to Claim 277 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

279. A targeted formulation according to Claim 278 wherein said perfluorocarbon gas is selected from the group consisting of perfluoropropane and perfluorobutane.

280. A targeted formulation according to Claim 279 wherein said perfluorocarbon gas comprises perfluorobutane.

281. A targeted formulation according to Claim 122 wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material.

282. A targeted formulation according to Claim 281 wherein said targeting ligand is selected from the group consisting of proteins, peptides and saccharides.

283. A targeted formulation according to Claim 282 wherein said targeting ligand is selected from the group consisting of proteins and peptides.

284. A targeted formulation according to Claim 283 wherein said targeting ligand comprises a peptide.

285. A targeted formulation according to Claim 284 wherein said peptide comprises a sequence selected from the group consisting of Arg-Gly-Asp and Lys-Gln-Ala-Gly-Asp-Val.

286. A targeted formulation according to Claim 286 wherein said targeting ligand comprises the sequence Arg-Gly-Asp.

287. A targeted formulation according to Claim 122 wherein said receptors comprise the glycoprotein GPIIbIIIa receptor.

288. A targeted formulation according to Claim 287 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of no greater than about 10^{-3} molar.

289. A targeted formulation according to Claim 288 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of less than about 10^{-3} molar.

290. A targeted formulation according to Claim 289 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-9} molar to less than about 10^{-3} molar.

291. A targeted formulation according to Claim 290 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-7} molar to about 10^{-5} molar.

292. A targeted formulation according to Claim 291 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of about 10^{-6} molar.

293. A method according to Claim 127 wherein said vesicles comprise lipid vesicles.

294. A method according to Claim 293, wherein said lipid vesicles comprise a phospholipid.

295. A method according to Claim 294 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.

296. A method according to Claim 295 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

297. A method according to Claim 296 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.

298. A method according to Claim 295 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoylphosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.

299. A method according to Claim 298 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.

300. A method according to Claim 295 wherein said phosphatidic acid comprises dipalmitoylphosphatidic acid.

301. A method according to Claim 293 wherein said lipid vesicles further comprise a polymer.

302. A method according to Claim 301 wherein said polymer comprises a hydrophilic polymer.

303. A method according to Claim 302 wherein said polymer comprises polyethylene glycol.

304. A method according to Claim 127 wherein said vesicles comprise protein vesicles.

305. A method according to Claim 304 wherein said protein comprises albumin.

306. A method according to Claim 127 wherein said vesicles comprise polymer vesicles.

307. A method according to Claim 306 wherein said polymer comprises synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, ε-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, propylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-

amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.

308. A method according to Claim 307 wherein said polymer comprises synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(ε-caprolactone), epoxy resin, poly(ethylene oxide), poly(propylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethyl-methacrylate and polystyrene-polyacrylonitrile.

309. A method according to Claim 308 wherein said polymer comprises polyvinylidene-polyacrylonitrile copolymer.

310. A method according to Claim 127 wherein said fluorinated gas comprises a perfluorocarbon.

311. A method according to Claim 310 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

312. A method according to Claim 311 wherein said perfluorocarbon gas is selected from the group consisting of perfluoropropane and perfluorobutane.

313. A method according to Claim 312 wherein said perfluorocarbon gas comprises perfluorobutane.

314. A method according to Claim 127 wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material.

315. A method according to Claim 314 wherein said targeting ligand is selected from the group consisting of proteins, peptides and saccharides.

316. A method according to Claim 315 wherein said targeting ligand is selected from the group consisting of proteins and peptides.

317. A method according to Claim 316 wherein said targeting ligand comprises a peptide.

318. A method according to Claim 317 wherein said peptide comprises a sequence selected from the group consisting of Arg-Gly-Asp and Lys-Gln-Ala-Gly-Asp-Val. SEQ ID NO 1

319. A method according to Claim 318 wherein said targeting ligand comprises the sequence Arg-Gly-Asp.

320. A method according to Claim 127 wherein said receptors comprise the glycoprotein GPIIbIIIa receptor.

321. A method according to Claim 320 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of no greater than about 10^{-3} molar.

322. A method according to Claim 321 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of less than about 10^{-3} molar.

323. A method according to Claim 322 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-9} molar to less than about 10^{-3} molar.

324. A method according to Claim 323 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-7} molar to about 10^{-5} molar.

325. A method according to Claim 324 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of about 10^{-6} molar.

326. A method according to Claim 127 further comprising the administration of a sufficient amount of ultrasound energy to induce rupture of said vesicles.

327. A method according to Claim 326 wherein said targeting ligand targets the glycoprotein GPIIbIIIa receptor.

328. A method according to Claim 327 wherein said glycoprotein GPIIbIIIa receptor is associated with a thrombus.

329. A method according to Claim 328 wherein the amount of said ultrasound energy is also sufficient to stimulate lysis of said thrombus.

330. A method according to Claim 329 wherein said vesicles comprise lipid vesicles.

331. A method according to Claim 330, wherein said lipid vesicles comprise a phospholipid.

332. A method according to Claim 331 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.

333. A method according to Claim 332 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

334. A method according to Claim 333 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.

335. A method according to Claim 332 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoyl-phosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoyl-phosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.

336. A method according to Claim 335 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.

337. A method according to Claim 332 wherein said phosphatidic acid comprises dipalmitoylphosphatidic acid.

338. A method according to Claim 330 wherein said lipid vesicles further comprise a polymer.

339. A method according to Claim 338 wherein said polymer comprises a hydrophilic polymer.

340. A method according to Claim 339 wherein said polymer comprises polyethylene glycol.

341. A method according to Claim 329 wherein said vesicles comprise protein vesicles.

342. A method according to Claim 340 wherein said protein comprises albumin.

343. A method according to Claim 329 wherein said vesicles comprise polymer vesicles.

344. A method according to Claim 343 wherein said polymer comprises synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, ε-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, propylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.

345. A method according to Claim 344 wherein said polymer comprises synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(ε-caprolactone), epoxy resin, poly(ethylene oxide), poly(propylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethyl-methacrylate and polystyrene-polyacrylonitrile.

346. A method according to Claim 345 wherein said polymer comprises polyvinylidene-polyacrylonitrile copolymer.

347. A method according to Claim 329 wherein said fluorinated gas comprises a perfluorocarbon.

348. A method according to Claim 347 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

349. A method according to Claim 348 wherein said perfluorocarbon gas is selected from the group consisting of perfluoropropane and perfluorobutane.

350. A method according to Claim 349 wherein said perfluorocarbon gas comprises perfluorobutane.

Sub C17

351. A method according to Claim 329 wherein said targeting ligand comprises the sequence Arg-Gly-Asp.

352. A method according to Claim 351 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of no greater than about 10^{-3} molar.

353. A method according to Claim 352 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of less than about 10^{-3} molar.

354. A method according to Claim 353 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-9} molar to less than about 10^{-3} molar.